Protalix Total Assets from 2010 to 2025

PLX Stock

USD 2.49 0.13 5.51%

Protalix Biotherapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 52.1 M in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1997-03-31

Previous Quarter

61.6 M

Current Value

73.4 M

Quarterly Volatility

36.2 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1 M, Selling General Administrative of 42.8 M or Other Operating Expenses of 32.3 M, as well as many indicators such as Price To Sales Ratio of 2.43, Dividend Yield of 0.0 or PTB Ratio of 3.0. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.

Check out the analysis of Protalix Biotherapeutics Correlation against competitors.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Latest Protalix Biotherapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Protalix Biotherapeutics over the last few years. Total assets refers to the total amount of Protalix Biotherapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Protalix Biotherapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Protalix Biotherapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 73.42 M

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Protalix Total Assets Regression Statistics

	Arithmetic Mean	68,451,445
	Geometric Mean	61,172,973
	Coefficient Of Variation	34.95
	Mean Deviation	17,212,124
	Median	73,417,000
	Standard Deviation	23,926,986
	Sample Variance	572.5T
	Range	106M
	R-Value	0.06
	Mean Square Error	611.4T
	R-Squared	0
	Significance	0.83
	Slope	286,696
	Total Sum of Squares	8587.5T

Protalix Total Assets History

	2025	52.1 M
	2024	73.4 M
	2023	84.4 M
	2022	55.8 M
	2021	73.7 M
	2020	67.9 M
	2019	45.4 M

Other Fundumenentals of Protalix Biotherapeutics

Intangibles To Total Assets

Protalix Biotherapeutics Total Assets component correlations

	Total Assets	Net Debt	Net Receivables	Total Liab	Total Current Assets	Total Stockholder Equity	Retained Earnings	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Cash And Equivalents	Net Working Capital	Capital Stock
Total Assets		-0.21	-0.03	0.54	0.99	0.05	-0.23	0.5	0.56	0.09	0.06	0.5	-0.1	0.31	0.52	0.08	0.16	0.01	0.3	0.17	0.22	0.2
Net Debt	-0.21		0.12	0.23	-0.16	-0.45	-0.34	0.21	-0.28	-0.06	0.08	-0.56	0.14	-0.51	0.18	0.28	-0.33	-0.32	-0.29	-0.45	-0.71	-0.49
Net Receivables	-0.03	0.12		0.06	-0.12	-0.09	-0.6	-0.27	-0.02	0.53	0.22	0.16	0.12	-0.22	0.07	0.45	-0.55	-0.17	-0.12	-0.55	-0.29	-0.45
Total Liab	0.54	0.23	0.06		0.52	-0.76	-0.11	0.39	0.45	0.32	-0.31	0.3	0.38	-0.5	0.61	-0.28	0.04	0.32	-0.49	0.29	-0.08	0.19
Total Current Assets	0.99	-0.16	-0.12	0.52		0.07	-0.2	0.5	0.57	-0.04	0.06	0.37	-0.11	0.32	0.57	0.08	0.15	0.02	0.29	0.2	0.24	0.23
Total Stockholder Equity	0.05	-0.45	-0.09	-0.76	0.07		-0.1	-0.13	-0.13	-0.33	0.44	-0.02	-0.54	0.8	-0.3	0.35	0.06	-0.4	0.74	-0.26	0.2	-0.15
Retained Earnings	-0.23	-0.34	-0.6	-0.11	-0.2	-0.1		0.06	-0.03	-0.27	-0.57	0.07	-0.2	0.04	-0.15	-0.87	0.73	0.62	-0.11	0.78	0.52	0.73
Short Term Debt	0.5	0.21	-0.27	0.39	0.5	-0.13	0.06		0.08	0.08	0.0	0.28	-0.2	0.03	-0.01	-0.15	0.39	-0.2	0.22	0.08	-0.22	0.06
Common Stock	0.56	-0.28	-0.02	0.45	0.57	-0.13	-0.03	0.08		0.16	-0.36	0.28	0.17	0.06	0.38	-0.16	-0.08	0.42	-0.02	0.44	0.51	0.63
Accounts Payable	0.09	-0.06	0.53	0.32	-0.04	-0.33	-0.27	0.08	0.16		0.08	0.61	0.35	-0.14	-0.19	0.04	-0.13	-0.09	-0.12	-0.03	-0.19	-0.13
Short Term Investments	0.06	0.08	0.22	-0.31	0.06	0.44	-0.57	0.0	-0.36	0.08		-0.05	-0.22	0.34	-0.25	0.69	-0.29	-0.76	0.47	-0.49	-0.34	-0.65
Property Plant Equipment	0.5	-0.56	0.16	0.3	0.37	-0.02	0.07	0.28	0.28	0.61	-0.05		-0.11	0.27	-0.15	-0.24	0.47	0.03	0.24	0.28	0.21	0.25
Current Deferred Revenue	-0.1	0.14	0.12	0.38	-0.11	-0.54	-0.2	-0.2	0.17	0.35	-0.22	-0.11		-0.44	0.19	0.07	-0.52	0.22	-0.43	0.04	-0.09	-0.04
Net Tangible Assets	0.31	-0.51	-0.22	-0.5	0.32	0.8	0.04	0.03	0.06	-0.14	0.34	0.27	-0.44		-0.26	0.17	0.27	-0.28	0.62	0.06	0.29	0.05
Long Term Debt	0.52	0.18	0.07	0.61	0.57	-0.3	-0.15	-0.01	0.38	-0.19	-0.25	-0.15	0.19	-0.26		-0.05	-0.15	0.38	-0.29	0.15	0.2	0.16
Capital Surpluse	0.08	0.28	0.45	-0.28	0.08	0.35	-0.87	-0.15	-0.16	0.04	0.69	-0.24	0.07	0.17	-0.05		-0.71	-0.72	0.35	-0.82	-0.42	-0.72
Short Long Term Debt	0.16	-0.33	-0.55	0.04	0.15	0.06	0.73	0.39	-0.08	-0.13	-0.29	0.47	-0.52	0.27	-0.15	-0.71		0.18	0.21	0.58	0.28	0.5
Long Term Debt Total	0.01	-0.32	-0.17	0.32	0.02	-0.4	0.62	-0.2	0.42	-0.09	-0.76	0.03	0.22	-0.28	0.38	-0.72	0.18		-0.51	0.73	0.68	0.73
Net Invested Capital	0.3	-0.29	-0.12	-0.49	0.29	0.74	-0.11	0.22	-0.02	-0.12	0.47	0.24	-0.43	0.62	-0.29	0.35	0.21	-0.51		-0.17	0.15	-0.03
Cash And Equivalents	0.17	-0.45	-0.55	0.29	0.2	-0.26	0.78	0.08	0.44	-0.03	-0.49	0.28	0.04	0.06	0.15	-0.82	0.58	0.73	-0.17		0.73	0.88
Net Working Capital	0.22	-0.71	-0.29	-0.08	0.24	0.2	0.52	-0.22	0.51	-0.19	-0.34	0.21	-0.09	0.29	0.2	-0.42	0.28	0.68	0.15	0.73		0.8
Capital Stock	0.2	-0.49	-0.45	0.19	0.23	-0.15	0.73	0.06	0.63	-0.13	-0.65	0.25	-0.04	0.05	0.16	-0.72	0.5	0.73	-0.03	0.88	0.8

Click cells to compare fundamentals

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	73.4 M	52.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC